Protocol No.: D926PC00001
- Title
- A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-Ll Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)
- Principal Investigator
- Safi, Danish
- Phase
- III
- Age Group
- Adult
- Applicable Disease Site
- Breast Cancer
- Participating Institution
- Mary Babb Randolph Cancer Center
- Contact
- Emily Hawkins, BSN
- Research Nurse
- Phone: +1 304-293-7375
- Email: eswiger1@hsc.wvu.edu